RFL.US Rafael Holdings, Inc.

Real Estate Real Estate Management & Development USA Stocks
0.9274 USD
Close of Nov 17, 2026
0.8907 3.96
Market cap
USD 47.7M
P/E
-
P/B
0.76x
ROE
-44.7%
Dividend yield
-
Fundamental score
-

Ratios use the latest price and the fiscal year ending Jul 2026.

Is RFL.US undervalued?

Graham number

The Graham number of Rafael Holdings, Inc. cannot be estimated reliably (it needs positive earnings and book value).

Graham number = √(22.5 × EPS × book value per share): the most a defensive investor should pay according to Benjamin Graham. An estimate, not a recommendation to buy or sell. How is it calculated?

Rafael Holdings, Inc. fundamental analysis

No fundamental analysis for Rafael Holdings, Inc. yet.

Rafael Holdings, Inc. stock price

Prices on the chart can differ slightly from the closing prices StockSummer uses for its ratios.

About Rafael Holdings, Inc.

Rafael Holdings, Inc. primarily engages in holding interests in clinical and early-stage pharmaceutical companies in the United States and Israel. It operates in three segments, Healthcare, Infusion Technology, and Real Estate. Its lead drug candidate is Trappsol Cyclo, which is in phase 3 clinical trial being evaluated for the potential treatment of Niemann-Pick Disease Type C (NPC), a rare, fatal and progressive genetic disorder; and CPI-613 (devimistat), a stable analog o…

Full company profile